Elaine Haynes is President and CEO of KaloCyte, Inc., a pre-clinical biotech startup developing an artificial red blood cell substitute that can be freeze-dried and stored for use when blood is not available. She has raised over $5M in investor funding and $14M in non-dilutive grant funding , moved the company to Baltimore and grew the team to 9 employees. She is a seasoned business leader with over 35 years of healthcare experience and extensive expertise with development and commercialization of complex pharmaceuticals including radiopharmaceuticals, medical devices, sterile products, and controlled substances. Ms. Haynes was with Mallinckrodt Pharmaceuticals for over 28 years. As VP of Alliance Management, she led the divestitures of Mallinckrodt’s contrast media and nuclear imaging businesses, delivering nearly $1 billion in total transaction value. Prior roles include Vice President & General Manager where she led teams in North and South America and Global Marketing, Marketing Director, Training Manager, and Pharmacist with Board Certification in Nuclear Pharmacy. She has a BS in Pharmacy from St. Louis College of Pharmacy and an MBA from Washington University.